BrightEdge, the American Cancer Society’s impact venture capital arm, today announced a collaboration with Third Rock Ventures, a healthcare venture capital firm. The relationship connects a leading VC firm with a mission-driven strategic investment partner at the earliest stages of oncology company formation to broaden the impact of innovative oncology-focused startups.
Under the collaboration BrightEdge will have the opportunity to participate in the Series A and follow-on financing rounds of oncology-focused companies launched by TRV. BrightEdge, in partnership with ACS, will leverage its knowledge networks and research communities to deepen the impact of investments made in connection with the TRV-BrightEdge collaboration. TRV will also provide technical know-how and other resources to support the education of scientific founders and entrepreneurs in the ACS ecosystem. Read more.
